期刊文献+

使用Taqman技术监测慢性粒细胞白血病患者微小残留病灶 被引量:1

Detection of minimal residual in chronic myelocytic leukemia(CML)patients by Taqman technique
下载PDF
导出
摘要 目的动态的监测bcr-abl融合基因mRNA表达水平以及评估经格列卫治疗后的慢性粒细胞白血病(CML)患者微小残留病灶。方法荧光定量RT-PCR法(Q-RT-PCR)检测bcr-abl融合基因mRNA表达水平,收集来自广州金域的34例CML患者(包括经格列卫治疗后缓解病人17例,未经治疗病人17例)。CML患者的检测结果与其他良性血液病患者进行比较,并且结合临床表现,得到CML和其它非白血病病人中bcr-abl L表达信息,以及在慢性粒细胞白血病的治疗中微小残留病灶的重要意义。结果在CML病人中bcr-abl融合基因表达阳性率为88.3%(30/34),在其他的良性血液病中无表达。我们也能观察到经格列卫治疗的病人有一定的治疗效果,经格列卫治疗的病人bcr-abl融合基因的表达水平较未经治疗者明显降低(P<0.05)。结论 Q-RT-PCR法是检测慢性粒细胞白血病微小残留病灶的重要方法,BCR-ABL融合基因可以做为CML的分子标志。 Objective To detect the expression level of mRNA of bcr-abl fusion gene dynamical ly, and evaluate minimal residual disease (MRD) after therapy by Glivec (Imatinib Mesylate Capsules) for the patients of chronic myelocytic leukemia (CML). Methods Expression levels of bcr-abl fusion gene mRNA was detected by Real Time Quantitative PCR (RQ-PCR) technique. 34 samples from CML patients (including 17 patients treated with Glivec and 17 untreated patients) were collected from Kingmed. The expression levels of bcr-abl fusion gene mRNA CML patients were compared with that of the patients with other benign blood tumors, and combined with clinical situation, to explore the correlation of expression of bcr-abl between CML patients and others, and the significance of minimal residual disease (MRD) on CML's therapy. Results Expression of bcr-abl was 88.3% (30/34) in CML, and no expression in the patients with benign blood disease was found. The patients treated with Glivec who showed improvement was observed, too. The expression of bcr-abl is lower than those untreated patients (P〈0.05). Conclusion RQ-PCR was the suitable method for monitored MRD in CML, bcr-abl could serve as a molecular mark for CML.
出处 《分子诊断与治疗杂志》 2014年第4期239-244,共6页 Journal of Molecular Diagnostics and Therapy
基金 广东省医学科研基金(A2012603)
关键词 慢性粒细胞白血病 BCR-ABL融合基因 微小残留病灶 荧光定量PCR Chronic Myelocytic Leukemia bcr-abl Minimal Residual Disease (MRD) RQ- PCR
  • 相关文献

参考文献5

二级参考文献19

  • 1吴炜,薛永权,吴亚芳,潘金兰,沈娟.Ph染色体阳性慢性粒细胞白血病衍生9号染色体缺失的FISH研究[J].中华血液学杂志,2006,27(3):183-186. 被引量:12
  • 2姚利,陈子兴,岑建农,何军,邱桥成,鲍晓晶,袁晓妮.应用实时定量逆转录聚合酶链反应方法检测急性早幼粒细胞白血病患者PML-RARα基因转录本的临床意义[J].中华血液学杂志,2006,27(11):773-775. 被引量:8
  • 3杨天楹 见:张之南 沈悌 主编.急性白血病疗效标准[A].见:张之南,沈悌,主编.血液病诊断及疗效标准,第2版[C].北京:科学出版社,1998.215.
  • 4Mitelman F,ed. An international system for human cytogenetic nomencla2ture [ M ]. Basel : Karger S, 1995.
  • 5Cuneo A,Bigoni R, Emmanuel B, et al. Fluorescence in situ hybridization for the detection and monitoring of the PhO positive clone in chronic myelogenous leukemia:comparison with metaphase banding a- nalysis [J]. Leukemia,1998,12 (11) :1718.
  • 6Sinclair PB, Green AR, Grace C, et al. Improved sensitivity of BCROABL detection:a triple probe three color fluorescence in situ hybridization system [ J ]. Blood, 1997,90 (4) : 1395.
  • 7Cohen N, Novikov I, Hardan I, et al. Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization [ J ]. Cancer Genet Cytogenet,2000,123 (2) :102.
  • 8Gleissner B,Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acure B-lineage lymphoblastic leukemia:a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis[ J]. Blood,2002,99(5 ): 1536
  • 9Mensink E, van de Locht A, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR [ J ]. Br J Haematol, 1998,102 (3) :768
  • 10Saglio G, Pane F, Gottardi E, et al. Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis [ J ].Blood, 1996,87 ( 3 ): 1075

共引文献16

同被引文献11

  • 1秦亚溱,刘艳荣,李金兰,王卉,常艳,付家瑜,阮国瑞,史惠琳,丘镜滢,陆道培,陈珊珊.两例Ph染色体阳性慢性粒细胞白血病患者具有少见型bcr/abl融合基因[J].中华血液学杂志,2004,25(7):409-412. 被引量:6
  • 2Burmeister T, Maurer J, Aivado M, et al. Quality as- surance in RT-PCR-based BCR/ABL diagnostics-re- sults of an interlaboratory test and a standardization approach[J]. Leukemia, 2000,14 (10) : 1850-1856.
  • 3Burmeister T,Reinhardt R. A multiplex PCR for im- proved detection of typical and atypical BCR-ABL fu- sion transcripts[J]. Leuk Res,2008,32(4):579-585.
  • 4Sugimoto T, Ijima K, Hisatomi H, et al. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron lb sequence[J]. Am J Hematol,20O4,77(2) : 164-166.
  • 5Moreno MP,Cortinas MM,Bonomi R,et al. A novel BCR-ABL fusion transcript (e15a2) in 2 patients with atypical chronic myeloproliferative syndrome [ J ]. Blood,2001,97(11) :3668-3669.
  • 6Iwata S, Mizutani S, Nakazawa S, et al. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ ABL transcript lacking ABL exon a2 [J]. Leukemia, 1994,8(10) :1696-1702.
  • 7Link-Lenczowska D, Sacha T, Zawada M, et al. Atypi- cal BCR-ABL transcripts in patients with chronic my-eloid leukemia--the scheme for the diagnosis and mo- nitoring of minimal residual disease[J]. Przegl Lek, 2014,71(5) :258-262.
  • 8Volpe G, Cignetti A, Panuzzo C, et al. Alternative BCR/ABL splice variants in Philadelphia chromo- some-positive leukemias result in novel tumor-spe- cific fusion proteins that may represent potential targets for immunotherapy approaches [J]. Cancer Res,2007,67(11) :5300-5307.
  • 9Stankov K, Mihajlovic D, Stanimirov B, et al. Quanti- tative real time-polymerase chain reaction method in Bcr-Abl translocation diagnostics [J ]. J BUON, 2010,15 (2) : 318-322.
  • 10谷红丽,王进,秦正红,张日.慢性粒细胞白血病BCR-ABL融合类型的研究及其临床意义[J].苏州大学学报(医学版),2012,32(1):84-88. 被引量:5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部